Redeye provides its initial take on Surgical Science, with sales relatively in line with expectations, though marginally lower profit margin and somewhat higher OPEX, leading to a 24% miss on our EBIT estimates.
ANNONS
Redeye provides its initial take on Surgical Science, with sales relatively in line with expectations, though marginally lower profit margin and somewhat higher OPEX, leading to a 24% miss on our EBIT estimates.
